Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.

Published on Dec 1, 2011in Cancer6.86
· DOI :10.1002/CNCR.26198
Karim Chamie29
Estimated H-index: 29
(UCLA: University of California, Los Angeles),
Christopher S. Saigal49
Estimated H-index: 49
(UCLA: University of California, Los Angeles)
+ 4 AuthorsMark S. Litwin94
Estimated H-index: 94
Sources
Abstract
BACKGROUND: Clinical practice guidelines for the management of patients with bladder cancer encompass strategies that minimize morbidity and improve survival. In the current study, the authors sought to characterize practice patterns in patients with high-grade non–muscle-invasive bladder cancer in relation to established guidelines. METHODS: Surveillance, Epidemiology and End Results (SEER)-Medicare–linked data were used to identify subjects diagnosed with high-grade non–muscle-invasive bladder cancer between 1992 and 2002 who survived at least 2 years without undergoing definitive treatment (n = 4545). The authors used mixed-effects modeling to estimate the association and partitioned variation of patient sociodemographic, tumor, and provider characteristics with compliance measures. RESULTS: Of the 4545 subjects analyzed, only 1 received all the recommended measures. Approximately 42% of physicians have not performed at least 1 cystoscopy, 1 cytology, and 1 instillation of immunotherapy for a single patient nested within their practice during the initial 2-year period after diagnosis. After 1997, only use of radiographic imaging (odds ratio [OR], 1.19; 95% confidence interval [95% CI], 1.03-1.37) and instillation of immunotherapy (OR, 1.67; 95% CI, 1.39-2.01) were found to be significantly increased. Surgeon-attributable variation for individual guideline measures (cystoscopy, 25%; cytology, 59%; radiographic imaging, 10%; intravesical chemotherapy, 45%; and intravesical immunotherapy, 26%) contributes to this low compliance rate. CONCLUSIONS: There is marked underuse of guideline-recommended care in this potentially curable cohort. Unexplained provider-level factors significantly contribute to this low compliance rate. Future studies that identify barriers and modulators of provider-level adoption of guidelines are critical to improving care for patients with bladder cancer. Cancer 2011;. © 2011 American Cancer Society.
📖 Papers frequently viewed together
20096.86Cancer
9 Authors (Ralph Madeb, ..., Edward M. Messing)
8 Authors (Louis Denis)
References31
Newest
#1Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
#2Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 68
Last. Elizabeth Ward (ACS: American Cancer Society)H-Index: 93
view all 4 authors...
Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data regarding cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are age-...
Source
#1John M. Hollingsworth (UM: University of Michigan)H-Index: 28
#2Yun Zhang (UM: University of Michigan)H-Index: 15
Last. Brent K. Hollenbeck (UM: University of Michigan)H-Index: 62
view all 5 authors...
BACKGROUND: Given the uncertainty surrounding the optimal management for early stage bladder cancer, physicians vary in how they approach the disease. The authors of this report linked cancer registry data with medical claims to identify the sources of variation and opportunities for improving the value of cancer care. METHODS: By using data from the Surveillance, Epidemiology, and End Results-Medicare database (1992-2005), patients with early stage bladder cancer were abstracted (n = 18,276). T...
Source
#1John L. Gore (UW: University of Washington)H-Index: 42
#2Mark S. LitwinH-Index: 94
Last. Christopher S. SaigalH-Index: 49
view all 8 authors...
Background Evidence-based guidelines recommend radical cystectomy for patients with muscle-invasive bladder cancer. However, many patients receive alternate therapies, such as chemotherapy or radiation. We examined factors that are associated with the use of radical cystectomy for invasive bladder cancer and compared the survival outcomes of patients with invasive bladder cancer by the treatment they received. Methods From linked Surveillance, Epidemiology, and End Results–Medicare data, we iden...
Source
#1Seth A. Strope (UM: University of Michigan)H-Index: 21
#2Zaojun Ye (UM: University of Michigan)H-Index: 24
Last. Brent K. Hollenbeck (UM: University of Michigan)H-Index: 62
view all 4 authors...
BACKGROUND: Early stage bladder cancer is a heterogeneous disease with a variable risk of progression and mortality. Uncertainty surrounding the optimal care for these patients may result in a mismatch between disease risk and treatment intensity. METHODS: Using Surveillance, Epidemiology, End Results-Medicare data, we identified patients diagnosed with early stage bladder cancer (n = 24,980) between 1993 and 2002. We measured patients' treatment intensity by totaling all Medicare payments made ...
Source
#1Jakub Dobruch (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 7
#2Harry W. Herr (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 114
Source
#1Ralph Madeb (UR: University of Rochester)H-Index: 19
#2Dragan Golijanin (UR: University of Rochester)H-Index: 36
Last. Edward M. Messing (UR: University of Rochester)H-Index: 84
view all 9 authors...
Background Phase III clinical trials performed primarily outside the United States (U.S.) demonstrate that intravesical instillation of chemotherapy immediately following transurethral resection of a bladder tumor (TURB) decreases recurrence rates. We sought to determine whether U.S. urologists have adopted this practice, and its potential effect on costs of bladder cancer (BC) care.
Source
#1Sigurdur Gudjonsson (Lund University)H-Index: 25
#2Lars AdellH-Index: 3
Last. Fredrik LiedbergH-Index: 31
view all 12 authors...
Abstract Background To decrease recurrences in non–muscle-invasive bladder cancer (NMIBC), the European Association of Urology (EAU) guidelines recommend immediate, intravesical chemotherapy after transurethral resection (TUR) for all patients with Ta/T1 tumours. Objective To study the benefits of a single, early, intravesical instillation of epirubicin after TUR in patients with low- to intermediate-risk NMIBC. Design, setting, and participants In this prospective randomised multicentre trial, ...
Source
#1Kasonde Bowa (UNZA: University of Zambia)H-Index: 13
#2C WoodH-Index: 2
Last. M Chikwenya (UNZA: University of Zambia)H-Index: 3
view all 6 authors...
This is a retrospective study based on pathology reports of specimens reviewed at the University Teaching Hospital (UTH) pathology laboratory in Lusaka, Zambia, from January 1997 to December 2005. UTH is the main reference hospital in Zambia and has a catchment area covering 1.3 million people. The most common cancer among men was Kaposi's sarcoma followed by cancer of the eye, soft tissue sarcomas and cancer of the prostate. The most common cancer among women was cancer of the cervix, followed ...
Source
#1Willem OosterlinckH-Index: 32
#2Torvald Granfors (Sahlgrenska University Hospital)H-Index: 1
Last. Sten Holmäng (Sahlgrenska University Hospital)H-Index: 28
view all 5 authors...
Purpose: We studied whether a single instillation of epirubicin after transurethral bladder tumor resection would influence the interval to and size of the first recurrence.Materials and Methods: A total of 404 patients from 13 hospitals were randomized to 1 instillation of 50 mg epirubicin or placebo within 6 hours after transurethral resection of bladder tumors.Results: Of 155 evaluable patients in the epirubicin group 79 (51.0%) had recurrence compared to 95 of 152 (62.5%) in the placebo grou...
Source
#1David C. Miller (UCLA: University of California, Los Angeles)H-Index: 12
#2Christopher S. Saigal (UCLA: University of California, Los Angeles)H-Index: 49
Last. Mark S. LitwinH-Index: 94
view all 5 authors...
Background Despite their potential benefits to patients with kidney cancer, the adoption of partial nephrectomy and laparoscopy has been gradual and asymmetric. To clarify whether this trend reflects differences in kidney cancer patients or differences in surgeon practice styles, we compared the magnitude of surgeon-attributable variance in the use of partial nephrectomy and laparoscopic radical nephrectomy with that attributable to patient and tumor characteristics.
Source
Cited By121
Newest
#1Dan-Qi Wang (WHU: Wuhan University)H-Index: 2
#2Qiao Huang (WHU: Wuhan University)H-Index: 9
Last. Tong-Zu Liu (WHU: Wuhan University)H-Index: 17
view all 11 authors...
Background: Non-muscle-invasive bladder cancer (NMIBC) still poses a heavy load for resulting in many new cases which contribute significantly to medical costs. Although many NMIBC guidelines have been developed, the implementation of them remains deficient. Objective: To analyse Chinese urologists’ knowledge of and compliance with guidelines for NMIBC and identify associated factors. Methods: We conducted an online survey between August 2019 and January 2021. Respondents who were more than 65 y...
Source
#1Julian P. StruckH-Index: 7
#2Martin J.P. HennigH-Index: 5
Last. Philippe-Fabian Pohlmann (University of Freiburg)H-Index: 1
view all 20 authors...
Introduction null Guideline recommendations are meant to help minimize morbidity and to improve the care of nonmuscle invasive bladder cancer (NMIBC) patients but studies have suggested an underuse of guideline-recommended care. The aim of this study was to evaluate the level of adherence of German and Austrian urologists to German guideline recommendations. null Methods null A survey of 27 items evaluating diagnostic and therapeutic recommendations (15 cases of strong consensus and 6 cases of c...
Source
#1Abhishek Kumar (UCSD: University of California, San Diego)H-Index: 27
Abstract null null Background null Muscle-invasive bladder cancer (MIBC) remains undertreated despite multiple potentially curative options. Both radical cystectomy (RC) with or without neoadjuvant chemotherapy and trimodal therapy (TMT), including transurethral resection of bladder tumor followed by chemoradiotherapy, are standard treatments. null null null Objective null To evaluate real-world clinical outcomes of RC with neoadjuvant chemotherapy (RC-NAC), RC without NAC, TMT with National Com...
Source
#1Stephen B. Williams (UTMB: University of Texas Medical Branch)H-Index: 30
#2Lauren E. Howard (Durham University)H-Index: 19
Last. Stephen J. Freedland (Cedars-Sinai Medical Center)H-Index: 78
view all 7 authors...
Importance Management of high-risk non-muscle-invasive bladder cancer (NMIBC) represents a clinical challenge due to high failure rates despite prior bacillus Calmette-Guerin (BCG) therapy. Objective To describe real-world patient characteristics, long-term outcomes, and the economic burden in a population with high-risk NMIBC treated with BCG therapy. Design, Setting, and Participants This retrospective cohort study identified 412 patients with high-risk NMIBC from 63 139 patients diagnosed wit...
Source
Background Mini Chromosome Maintenance 5 (MCM5) is considered as a urinary biomarker of bladder cancer. ADXBLADDER is a commercially available test to detect MCM5 antibodies. Objective External validation of ADXBLADDER test as a urinary biomarker of histopathologically confirmed non-muscle invasive bladder cancer (NMIBC) recurrence. Methods The study enrolled 119 consecutive patients with a history of NMIBC and 37 healthy volunteers matched as controls. Single, full-void urine samples were colle...
Source
#1Diego M Carrion (UAM: Autonomous University of Madrid)H-Index: 7
#2Juan Gómez Rivas (UAM: Autonomous University of Madrid)H-Index: 13
Last. Luis Martínez-Piñeiro (UAM: Autonomous University of Madrid)H-Index: 24
view all 6 authors...
Abstract Introduction and objectives Recurrence rates for patients presenting with non-muscle invasive bladder carcinoma (NMIBC) can be as high as 60% during the first year after a transurethral resection of bladder tumor (TURBT). Currently, an immediate postoperative instillation of chemotherapy (IPOIC) is recommended for the prevention of recurrences in patients with low to intermediate risk disease. Although in real clinical practice this specific instillation of chemotherapy has many difficu...
Source
#1Keiichiro Mori (Jikei University School of Medicine)H-Index: 10
#2Noriyoshi Miura (Ehime University)H-Index: 5
Last. Shahrokh F. ShariatH-Index: 136
view all 12 authors...
Abstract Purpose: This systematic review assessed compliance to guidelines for the management of nonmuscle-invasive bladder carcinoma (NMIBC). Methods: The PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched in November 2019 in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Results: Fifteen studies incorporating a collective total of 10,575 NMIBC patients were eligible for inclusion in this systematic review. We found tha...
Source
#1Kenji Kuroda (National Defense Medical College)H-Index: 12
#2Shinsuke Tasaki (National Defense Medical College)H-Index: 8
Last. Keiichi Ito (National Defense Medical College)H-Index: 20
view all 6 authors...
A single immediate instillation of chemotherapy following transurethral resection of bladder tumor (TURBT) is effective in preventing intravesical recurrence (IVR) in patients with non-muscle-invasive urothelial bladder carcinoma (NMIBC). However, continuous saline bladder irrigation (CSBI) is also performed with a single instillation of chemotherapy (SIC), but its inhibitory effect on IVR remains unclear. In the present study, the effect of CSBI with concomitant SIC following TUR on IVR was eva...
Source
Background Clinical workup and treatment guidelines have been published by the National Comprehensive Cancer Network (NCCN) to ensure patients are treated uniformly and appropriately. This study sought to retrospectively review patients with a new diagnosis of sarcoma who were treated in a National Cancer Institute (NCI) designated center and determine compliance rates with guidelines for sarcoma. Aim To evaluate our compliance of NCCN sarcoma guidelines at a major NCI designated center and to r...
Source
#1T.M. RippingH-Index: 1
#2Lambertus A. Kiemeney (Radboud University Nijmegen)H-Index: 136
Last. Katja K.H. Aben (Radboud University Nijmegen)H-Index: 61
view all 5 authors...
BACKGROUND: Despite the embedding of bladder cancer management in European guidelines, large variation in clinical practice exists for applied diagnostics and treatments. This variation may affect patients' outcomes including complications, disease recurrence, progression, survival, and health-related quality of life (HRQL). Lack of detailed clinical data and HRQL data hampers a comprehensive evaluation of bladder cancer care. Through prospective data registration, this study aims to provide ins...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.